Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fibrous dysplasia.

Eckhard Schoenau1, Frank Rauch

  • 1Children's Hospital, University of Cologne, Germany. Eckhard.Schoenau@medizin.uni-koeln.de

Hormone Research
|June 18, 2002
PubMed
Summary
This summary is machine-generated.

Fibrous dysplasia (FD) treatment with bisphosphonates shows promise for reducing bone pain and improving bone density. Further standardized studies are needed to confirm efficacy, especially in pediatric patients with this rare bone disorder.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Splice Variant in ERGIC1 Causes Arthrogryposis Multiplex Congenita-Characterization Using Urine-Derived Cells.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same author

Characterisation of Urine-Derived Cells for the Molecular Diagnosis of Rare Disorders.

International journal of molecular sciences·2026
Same author

Milestone Attainment in Young Children With Arthrogryposis Multiplex Congenita: Developmental Profile and Associated Factors.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same author

Expanding the Autosomal Recessive Hypophosphatemic Rickets Type I Carrier Phenotype and Adult Treatment with Burosumab.

Calcified tissue international·2026
Same author

Impact of whole-body vibration training on gait in patients with progressive multiple sclerosis: a pilot randomised study.

BMJ neurology open·2026
Same author

Factors Associated With Functional Mobility in 256 Children With Arthrogryposis Multiplex Congenita: A Multicentric Cross-Sectional Study.

Archives of physical medicine and rehabilitation·2025
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

Area of Science:

  • Bone biology
  • Genetics
  • Pharmacology

Background:

  • Fibrous dysplasia (FD) is a congenital, non-inheritable bone disorder characterized by expanding fibrous lesions.
  • It results from somatic activating mutations in the Gs alpha protein (Gsalpha), leading to abnormal bone matrix production and lesion spread by osteoclasts.

Purpose of the Study:

  • To evaluate the efficacy of bisphosphonate treatment in patients with fibrous dysplasia.
  • To assess the impact of bisphosphonates on bone pain, biochemical markers, and radiographic findings in FD.

Main Methods:

  • Observational study of bisphosphonate treatment.
  • Assessment of bone pain intensity, bone turnover markers, and radiographic changes.

Main Results:

Related Experiment Videos

  • Bisphosphonate treatment led to decreased bone pain intensity in most patients.
  • A reduction in biochemical markers of bone turnover was observed.
  • Radiographic evidence of 'refilling of osteolytic sites' occurred in approximately half of the patients.

Conclusions:

  • Bisphosphonate therapy, particularly pamidronate, appears beneficial for managing symptoms in severely affected FD patients, including children and adolescents.
  • Further standardized, large-scale studies are necessary to fully elucidate the long-term effects and optimal use of bisphosphonates in FD treatment.